SLCO1B1 and acute lymphoblastic leukemia: The importance of both pharmacogenetic and clinical factors has been already shown in leukemia treatment, with SLCO1B1 genetic variability explaining 10.7% and treatment arm explaining ~17% of interpatient variability in MTX clearance among patients with acute lymphoblastic leukemia (Ramsey et al., 2012).